Phase I trial HMR code: 23-007

ISRCTN	ISRCTN10047421
DOI	https://doi.org/10.1186/ISRCTN10047421
ClinicalTrials.gov (NCT)	Nil known
Clinical Trials Information System (CTIS)	Nil known
Integrated Research Application System (IRAS)	1008807
Protocol serial number	IRAS 1008807 HMR code: 23-007
Sponsor	Gedeon Richter (Hungary)
Funder	Gedeon Richter

Submission date: 17/01/2024
Registration date: 22/01/2024
Last edited: 22/01/2024

Recruitment status: No longer recruiting
Overall study status: Deferred
Condition category: Other

Prospectively registered

Protocol

Statistical analysis plan

Results

Individual participant data

Record updated in last year

Plain English summary of protocol

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Contact information

Dr Takahiro Yamamoto
Principal investigator

HMR
Cumberland Avenue
London
NW10 7EW
United Kingdom

ORCID ID	0000-0001-9121-0836
Phone	+44 (0)208 961 4130
Email	rec@hmrlondon.com

Dr Gedeon Richter Plc Medical Information Scientific Service
Scientific

Gedeon Richter Plc.
Gyömrői út 19-21.
Budapest
H-1103
Hungary

Phone	+36 1 5057032
Email	medinfo@richter.hu

Dr Balázs Lázár
Public

Gedeon Richter Plc.
Gyömrői út 19-21.
Budapest
H-1103
Hungary

Phone	+36 204162804
Email	RA.ctaRichter@richter.hu

Study information

Primary study design	Interventional
Study design	First-in-human safety, pharmacokinetics, and pharmacodynamics trial in up to 176 healthy volunteers
Secondary study design	Randomised controlled trial; open label cross over trial
Study type	Participant information sheet
Scientific title	Phase I trial HMR code: 23-007 [The full scientific title will be published within 30 months after the end of the trial]
Study objectives	The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
Ethics approval(s)	Approved 12/01/2024, South Central – Oxford A REC (Ground Floor, Temple Quay House, 2 The Square, Bristol, BS1 6PN, United Kingdom; +44 (0)207 1048171; oxforda.rec@hra.nhs.uk), ref: 23/SC/0316
Health condition(s) or problem(s) studied	The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
Intervention	The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
Intervention type	Drug
Phase	Phase I
Drug / device / biological / vaccine name(s)	The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
Primary outcome measure(s)	The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
Key secondary outcome measure(s)	The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
Completion date	25/07/2025

Eligibility

Participant type(s)	Healthy volunteer
Age group	Adult
Lower age limit	18 Years
Sex	All
Target sample size at registration	176
Key inclusion criteria	Healthy human volunteer
Key exclusion criteria	The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
Date of first enrolment	24/01/2024
Date of final enrolment	25/04/2025

Locations

Countries of recruitment

United Kingdom
England

Study participating centre

HMR

Cumberland Avenue
Park Royal
London
NW10 7EW
United Kingdom

Results and Publications

Individual participant data (IPD) Intention to share	No
IPD sharing plan summary	Not expected to be made available
IPD sharing plan	The datasets generated and/or analysed during the current study are not expected to be made available because of their high commercial sensitivity and the negligible benefit to the public of publication of results of non-therapeutic clinical trials.

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes

Editorial Notes

22/01/2024: Study's existence confirmed by the MHRA.